CGI’s Select One™ program offers unique solutions to investigators, CROs, and biopharma companies in support of their Phase 1-3 clinical trial testing needs. As a leader in personalized oncology, CGI provides disease- specific biomarker knowledge, proprietary assays, and state of the art oncology laboratory services. We believe the integration of clinical information with drug discovery is critical to providing customized solutions for patient stratification and treatment. Below is an overview of our services:

  • Customizable tests and techniques to improve clinical trial design
  • Time sensitive trial test development
  • Rapid proof-of-concept studies
  • Dependable results from early phase initiatives
  • Microarrays to provide enhanced genomic information
  • Enhanced understanding of complex diseases at earlier stages

Our clinical team is backed by CGI’s strong R&D background, which has led to the development of innovative and proprietary testing along with an in-depth understanding of complex cancer states. We leverage this knowledge and experience in oncology-based testing to provide solutions that lead to effective patient stratification, increased responder population, endpoints validation and optimization.

The size of our company enables us to respond quickly to the needs of clients and provide them with high quality specialized outcomes for clinical trials. Our laboratory, which is CLIA approved and CAP accredited ensures the service we provide to clients is accurate and reliable. Through our focus and dedication to innovation and personalized oncology, clients also benefit from our:

  • World-class expertise in oncology
  • Strong oncology-focused R&D program
  • Experience developing custom DNA probe panels and microarrays
  • Adaptability and quick response to client needs
  • Renown Scientific Advisory Board

For more information please contact us at contact@cancergenetics.com or visit our website www.cancergenetics.com.